Selected insights

Below are thought leadership pieces focused on structured products. These accounts provide insights from experts who have played a pivotal role in the field.

Tag: Underlyings

Analysis: oil-linked structured products

The price of crude oil remains a preferred asset when it comes to allocation around commodities; we look at the different alternatives in the structured products market to deploy this commodity in investment portfolios.

02 Jul 2024 by Suzi Hampson - FVC

StructrPro: falling underlyings

The underlying exposure and the payoff structure are two of the key elements of structured products seeking to invest in the market. But when markets go south protection comes to the fore as a critical feature to minimise the impact of falling underlyings.

13 Feb 2024 by Tim Mortimer - FVC

HSCEI: Vega supply muted by lower issuance

Almost 70% of live products featuring the Hang Seng China Enterprises Index (HSCEI) are in safe territory and far from breaching their defensive barriers.

14 Nov 2023 by Pablo Conde

Analysis: single stock-linked products - a valuable portfolio ‘sharpener’

Stock linked products are popular in many structured product markets worldwide.

05 Jun 2023 by Tim Mortimer - FVC

Pharma in structured products (part 5) - option trading strategies and delta hedging

The next section of our analysis focuses on call butterfly, iron condor, bull call spread and bear put Spread option strategies and how adequately their profit potential has been realised in the case of Teva Pharmaceutical (Teva), BioMarin Pharmaceutical (BMRN), HCA Healthcare (HCA), Merck (MRK), and Fresenius Medical Care (FMS).

26 Mar 2021 by Filip Dyankov

Pharma in structured products (part 4) – technical analysis of pharmaceutical stocks

In this article we apply the Donchian Channel on a sample of 16 stocks – Amgen, Bayer, Biogen, BioNTech, CSPC Pharmaceutical Group, CVS Health, Exact Sciences, Fresenius, Gilead Sciences, Merck, Moderna, Pfizer, Sanofi, Teladoc Health, UnitedHealth, and Vertex Pharmaceutical), as well as the Chakin Moneyflow Index and Aroon Up/Down indicator on a set of five securities.

25 Mar 2021 by Filip Dyankov

Pharma in structured products - issuance & sales

Underlying analysis of pharma-based structured products amid a challenging economic climate shows falling sales and issuance.

22 Mar 2021 by Filip Dyankov

Interested in how structured products intelligence can power your business?

Request Demo

Who we are

Launched in 2003, SRP is the leading provider of intelligence for the global structured product market, trusted by investment banks, hedge funds, product issuers and distributors, exchanges and asset managers.

Today, we enable market players to find any product from over 40 million in our database and easily analyse the market. Our news service and global events cover the latest insights into the structured products market and recognises industry leading talent through our awards programmes.

Learn more

( History of structured productsPrev FAQs - structured productsNext )